|Bid||5.25 x 1800|
|Ask||6.20 x 4000|
|Day's range||5.38 - 5.55|
|52-week range||5.31 - 10.05|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||12.94|
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
The underwhelming share price performance of CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) in the past three years would...